{
  "abstract": "Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) represent globally prevalent chronic hepatic conditions, in which gut dysbiosis acts as a key pathogenic driver through dysregulation of the gut-liver axis. Herbal medicines (HMs) are increasingly recognized as viable therapeutic candidates for MASLD/MASH, primarily through their ameliorative properties on gut-liver axis and pathophysiological pathways of intestinal microbiota. This review summarizes the pathogenesis of MASLD/MASH and the application of HMs in their treatment from the perspective of the gut-liver axis and intestinal microbiota. The progression of MASLD/MASH involves several pathological processes marked by modifications in the gut-liver axis, including compromised gut barrier function and increased intestinal permeability causing endotoxemia and inflammation, along with alterations in microbiota composition and gut microbiota-derived metabolites. This review further delineates the shared mechanisms within each class of compounds in HMs for ameliorating MASLD/MASH, highlights recent advances in the combined use of HMs and probiotics, and discusses the key issues and challenges associated with the clinical translation of HM-based preparations. These insights potentially catalyze the advancement of novel therapeutics targeting MASLD/MASH, while providing a translational framework for clinical application of HMs.",
  "abstract_shown": true,
  "affiliations": [
    "School of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou 510006, China.",
    "School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.",
    "School of Medicine, The Chinese University of Hong Kong-Shenzhen, Shenzhen 518172, China."
  ],
  "article_type": "review article",
  "arxiv": null,
  "author_total": 10,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Yiqin Mao"
    },
    {
      "affs": [
        0
      ],
      "name": "Caihong Wei"
    },
    {
      "affs": [
        0
      ],
      "name": "Yi Zhang"
    },
    {
      "affs": [
        0
      ],
      "name": "Yiqin Zheng"
    },
    {
      "affs": [
        0
      ],
      "name": "Ruifeng Ji"
    },
    {
      "affs": [
        1
      ],
      "name": "Ge Lin"
    },
    {
      "affs": [
        0
      ],
      "name": "Xin He"
    },
    {
      "affs": [
        2
      ],
      "name": "Yisheng He"
    },
    {
      "affs": [
        0
      ],
      "name": "Ji Yang"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Jiang Ma"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/94hsmwqrvnydy.bib",
  "cited_by": 0,
  "doi": "10.1016/j.chmed.2026.08.017",
  "fulltext_url": "https://europepmc.org/articles/PMC13712341",
  "id": "94hsmwqrvnydy",
  "issns": [
    "1674-6384",
    "2589-3610"
  ],
  "landing_url": "https://europepmc.org/article/MED/42948719",
  "language": "eng",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Review"
    ],
    [
      "openalex",
      "1312|Gut microbiota and health"
    ]
  ],
  "openalex": "W7204817271",
  "pdf_url": "https://europepmc.org/articles/PMC13712341?pdf=render",
  "pmcid": "PMC13712341",
  "pmid": "42948719",
  "published": "2026-08-31",
  "publisher": "Elsevier",
  "ris": "https://research.draconitic.com/paper/94hsmwqrvnydy.ris",
  "sources": [
    {
      "first_seen": "2026-10-31T00:20:35Z",
      "native_id": "MED:42948719",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42948719"
    },
    {
      "first_seen": "2026-10-31T12:22:56Z",
      "native_id": "PMC13712341",
      "source": "pmc",
      "url": "https://doi.org/10.1016/j.chmed.2026.08.017"
    }
  ],
  "subjects": [
    {
      "field": "biochemistry",
      "origin": "openalex:1312|Gut microbiota and health",
      "subfield": "molecular-biology"
    }
  ],
  "title": "Gut-liver axis and intestinal microbiota: Key targets of herbal medicines in treatment of MASLD/MASH.",
  "title_text": "Gut-liver axis and intestinal microbiota: Key targets of herbal medicines in treatment of MASLD/MASH.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-31T12:22:56Z",
  "url": "https://research.draconitic.com/paper/94hsmwqrvnydy",
  "venue": "Chinese herbal medicines",
  "versions": []
}